Share
array:24 [ "pii" => "S2387020616303631" "issn" => "23870206" "doi" => "10.1016/j.medcle.2016.06.045" "estado" => "S300" "fechaPublicacion" => "2016-05-20" "aid" => "3474" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2015" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2016;146:e57-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0025775315006582" "issn" => "00257753" "doi" => "10.1016/j.medcli.2015.11.032" "estado" => "S300" "fechaPublicacion" => "2016-05-20" "aid" => "3474" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2016;146:e57-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 26 "formatos" => array:2 [ "HTML" => 16 "PDF" => 10 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>" "titulo" => "Rabdomiólisis yatrógena en un paciente con cardiopatía isquémica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e57" "paginaFinal" => "e58" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Iatrogenic rhabdomyolysis in a patient with ischemic heart disease" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Raquel Cenjor Martín, Elena Gutiérrez-Madrid, Francisco Javier Martín-Sánchez, Rafael Cuervo Pinto" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Raquel" "apellidos" => "Cenjor Martín" ] 1 => array:2 [ "nombre" => "Elena" "apellidos" => "Gutiérrez-Madrid" ] 2 => array:2 [ "nombre" => "Francisco Javier" "apellidos" => "Martín-Sánchez" ] 3 => array:2 [ "nombre" => "Rafael" "apellidos" => "Cuervo Pinto" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020616303631" "doi" => "10.1016/j.medcle.2016.06.045" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616303631?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315006582?idApp=UINPBA00004N" "url" => "/00257753/0000014600000010/v1_201604290136/S0025775315006582/v1_201604290136/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2387020616303552" "issn" => "23870206" "doi" => "10.1016/j.medcle.2016.06.037" "estado" => "S300" "fechaPublicacion" => "2016-05-20" "aid" => "3441" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Med Clin. 2016;146:470" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Image in medicine</span>" "titulo" => "Leser-Trelat sign associated with pancreatic cancer" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "470" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Signo de Leser-Trélat asociado a cáncer pancreático" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 799 "Ancho" => 600 "Tamanyo" => 122599 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Ángel Cuervo Pinna" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Miguel Ángel" "apellidos" => "Cuervo Pinna" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775315006235" "doi" => "10.1016/j.medcli.2015.10.029" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315006235?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616303552?idApp=UINPBA00004N" "url" => "/23870206/0000014600000010/v1_201609110046/S2387020616303552/v1_201609110046/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2387020616303576" "issn" => "23870206" "doi" => "10.1016/j.medcle.2016.06.039" "estado" => "S300" "fechaPublicacion" => "2016-05-20" "aid" => "3458" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2016;146:e55" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Cyanoacrylate-related pulmonary embolism following transhepatic embolization of esophageal varices" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "e55" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Embolia pulmonar por cianoacrilato tras embolización transhepática de varices esofágicas" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Luis Gorospe Sarasúa, Frank Eric Farfán-Leal, Rubén Eduardo Pacios-Blanco, Raquel García-Latorre" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Luis" "apellidos" => "Gorospe Sarasúa" ] 1 => array:2 [ "nombre" => "Frank Eric" "apellidos" => "Farfán-Leal" ] 2 => array:2 [ "nombre" => "Rubén Eduardo" "apellidos" => "Pacios-Blanco" ] 3 => array:2 [ "nombre" => "Raquel" "apellidos" => "García-Latorre" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775315006429" "doi" => "10.1016/j.medcli.2015.11.016" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315006429?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616303576?idApp=UINPBA00004N" "url" => "/23870206/0000014600000010/v1_201609110046/S2387020616303576/v1_201609110046/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Iatrogenic rhabdomyolysis in a patient with ischemic heart disease" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e57" "paginaFinal" => "e58" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Raquel Cenjor Martín, Elena Gutiérrez-Madrid, Francisco Javier Martín-Sánchez, Rafael Cuervo Pinto" "autores" => array:4 [ 0 => array:3 [ "nombre" => "Raquel" "apellidos" => "Cenjor Martín" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Elena" "apellidos" => "Gutiérrez-Madrid" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Francisco Javier" "apellidos" => "Martín-Sánchez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:4 [ "nombre" => "Rafael" "apellidos" => "Cuervo Pinto" "email" => array:1 [ 0 => "rcuervopinto@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Urgencias, Hospital Universitario Central de Asturias, Oviedo, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Urgencias, Hospital Universitario Clínico San Carlos, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Rabdomiólisis yatrógena en un paciente con cardiopatía isquémica" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The recently published Acute Coronary Syndrome Management Guidelines<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> propose intensive combined therapies to achieve ambitious and specific goals.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> In relation to the management of antiplatelet drugs, the accepted combination consists of aspirin plus a P2Y12 platelet receptor blocker for at least the first year after the event.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> Among the latter, ticagrelor at doses of 90<span class="elsevierStyleHsp" style=""></span>mg/12<span class="elsevierStyleHsp" style=""></span>h has shown faster action, decreased likelihood of stent thrombosis and increased safety in patients without specific coronary studies or waiting to perform them<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> when compared to other drugs in its class, becoming the first alternative in the absence of contraindications in patients with moderate to high risk of ischemic events.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> However, one must take into account the possible drug interactions of this drug with other frequently used.</p><p id="par0010" class="elsevierStylePara elsevierViewall">We report the case of a 72-year-old man, with no drug allergies and a history of low risk prostate adenocarcinoma under monitoring by Radiation Oncology and unstable angina due to total occlusion of the middle segment of the left anterior descending artery, for which he underwent percutaneous revascularization with drug-eluting stent 3 months before his current Emergency Department consultation. He was discharged from the Cardiology ward under treatment with enalapril 10<span class="elsevierStyleHsp" style=""></span>mg/12<span class="elsevierStyleHsp" style=""></span>h, bisoprolol 5<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h, aspirin 300<span class="elsevierStyleHsp" style=""></span>mg/day, ticagrelor 90<span class="elsevierStyleHsp" style=""></span>mg/12<span class="elsevierStyleHsp" style=""></span>h and atorvastatin 40<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h. He went to the emergency department referring chest pain of mechanical characteristics during several days in the context of polymyalgia and malaise, with irrelevant physical examination and history of having added to his usual treatment clarithromycin 250<span class="elsevierStyleHsp" style=""></span>mg/12<span class="elsevierStyleHsp" style=""></span>h due to a respiratory infection a week before. A serial cardiac enzymes test was performed, which ruled out new ischemic events, although 15,141<span class="elsevierStyleHsp" style=""></span>U/l of serum creatine kinase was observed. After diagnosis of rhabdomyolysis, probably drug-induced, fluid therapy was initiated, and clarithromycin and atorvastatin were suspended, with clinical and laboratory improvement within a few days (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). He was discharged with the recommendation of reintroducing atorvastatin at lower doses, monitoring the levels of creatine kinase or replacing it by pravastatin.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">This case reflects an adverse event associated with the use of several drugs necessary and beneficial for the patient's basal disease<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">5,6</span></a> together with another drug prescribed for a specific use and limited time, but acting through the same metabolic pathway.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Ticagrelor works by inhibiting the prothrombotic effects of ADP on the platelet, antagonizing the P2Y12 receptor without the need of metabolic transformation.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">7</span></a> It has a faster action and less interpatient variability in plasma concentrations and antiplatelet effects than thienopyridines (ticlopidine, clopidogrel, prasugrel),<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">7</span></a> therefore its use is preferred to the latter ones. The main enzymes responsible for the formation of the active metabolite are cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, CYP3A5.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Atorvastatin is also metabolized by CYP3A4 and has high bioavailability (12%).<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a> As with other statins; the most significant safety issue is myopathy, which may progress into rhabdomyolysis.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a> Rhabdomyolysis is a rare but especially severe side effect associated with the use of statins, whose incidence is 1/1000 to 1/10,000 in patients with standard doses of statins.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Ticagrelor SmPC (Summary of Product Characteristics) describes the possible interaction with atorvastatin by increasing the levels of active metabolites of the latter.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">1,9</span></a> We only found one case reported of rhabdomyolysis associated with the interaction of ticagrelor and atorvastatin 80<span class="elsevierStyleHsp" style=""></span>mg/day with a time sequence of 2 months from the start of concomitant use of both drugs.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Macrolides are potent inhibitors of CYP3A4, so its use is contraindicated with ticagrelor (increases their levels)<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">7</span></a> and should be avoided with statins (increases their plasma concentrations).<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">6</span></a> Therefore, the associated use causes an increase in active metabolites of statins by indirect effect (macrolide-ticagrelor-statin) and direct effect (macrolide-statin).</p><p id="par0040" class="elsevierStylePara elsevierViewall">Our patient had remained asymptomatic since the start of treatment with atorvastatin and ticagrelor, starting with rhabdomyolysis one week after concomitant exposure to clarithromycin. This time sequence is what makes us conclude that this macrolide, through the mechanisms described, triggers an increase in statin levels, further enhanced by ticagrelor and causing rhabdomyolysis.</p><p id="par0045" class="elsevierStylePara elsevierViewall">This case leads to the consideration that it is necessary to take into account the interactions and side effects described when prescribing other drugs for the treatment of intercurrent common diseases regarding new therapies for secondary prevention of ischemic heart disease (in our patient, macrolides for a respiratory infection).</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Cenjor Martín R, Gutiérrez-Madrid E, Martín-Sánchez FJ, Cuervo Pinto R. Rabdomiólisis yatrógena en un paciente con cardiopatía isquémica. Med Clin (Barc). 2016;146:e57–e58.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Lab reference values \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">First day (initial consultation) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Third day \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Fifth day \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urea (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15–50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">52 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Creatinine (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.67–1.17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.18 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Estimated glomerular filtration rate (ml/min) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">60–140 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">54 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">53.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">54 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sodium (mmol/l) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">135–145 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">138 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">136 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">135 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Potassium (mmol/l) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.4–5.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Creatine kinase (U/l) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1–190 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15,141 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8601 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5684 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Creatine kinase MB (ng/ml) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1–5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">34.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">31.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Troponin I (ng/ml) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001–0.05 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.04 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.05 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.04 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1201888.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Lab tests progression after discontinuation of clarithromycin and atorvastatin.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Roffi" 1 => "C. Patrono" 2 => "M. Valgimigli" 3 => "F. Andreotti" 4 => "J.J. Bax" 5 => "M.A. Borger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehw180" "Revista" => array:4 [ "tituloSerie" => "Eur Heart J" "fecha" => "2015" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27141094" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109706008515" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diferencias en los resultados de la atención a los pacientes con síndrome coronario agudo con elevación del segmento ST (SCACEST) en función del acceso inicial a hospitales con o sin sala de hemodinámica en Andalucía" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Reina Toral" 1 => "M. Colmenero Ruiz" 2 => "C. García Pérez" 3 => "M. Expósito Ruiz" 4 => "E. de Antonio Martín" 5 => "C. Bermúdez Tamayo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Emergencias" "fecha" => "2014" "volumen" => "26" "paginaInicial" => "101" "paginaFinal" => "108" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Simons M, Cutlip D, Lincoff AM. Antiplatelet agents in acute non-ST elevation acute coronary syndromes. UpToDate. Available from: <a id="intr0010" class="elsevierStyleInterRef" href="http://www.uptodate.com/">http://www.uptodate.com/</a> [accessed 26.10.15]." ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interacciones medicamentosas de agentes hipolipemiantes: aproximación para establecer y valorar su relevancia clínica. Revisión estructurada" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "D. Franco" 1 => "Y. Henao" 2 => "M. Monsalve" 3 => "F. Gutiérrez" 4 => "J. Hincapié" 5 => "P. Amariles" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7399/FH.2013.37.6.1077" "Revista" => array:6 [ "tituloSerie" => "Farm Hosp" "fecha" => "2013" "volumen" => "37" "paginaInicial" => "539" "paginaFinal" => "557" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24256019" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relevancia clínica del tratamiento farmacológico completo precoz en el pronóstico del síndrome coronario agudo sin elevación del ST" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Fortuny" 1 => "I.J. Nuñez Gil" 2 => "J.C. García-Rubira" 3 => "B. Ruiz Mateos" 4 => "B. Ibañez" 5 => "N. Gonzalo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Emergencias" "fecha" => "2011" "volumen" => "23" "paginaInicial" => "461" "paginaFinal" => "467" "itemHostRev" => array:3 [ "pii" => "S073510971002526X" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biomarcadores en el paciente con dolor torácico: pasado, presente y futuro" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Rubini" 1 => "B. López" 2 => "S. Rubini" 3 => "C. Mueller" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Emergencias" "fecha" => "2014" "volumen" => "26" "paginaInicial" => "221" "paginaFinal" => "226" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">In vitro</span> evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition. Induction, and differential kinetics" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Zhou" 1 => "T.B. Andersson" 2 => "S.W. Grimm" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1124/dmd.110.037143" "Revista" => array:7 [ "tituloSerie" => "Drug Metab Dispos" "fecha" => "2011" "volumen" => "39" "paginaInicial" => "703" "paginaFinal" => "710" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21177984" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109706006103" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment. Aetiology and management" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.S. Stroes" 1 => "P.D. Thompson" 2 => "A. Corsini" 3 => "G.D. Vladiutiu" 4 => "F.J. Raal" 5 => "K.K. Ray" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehv043" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2015" "volumen" => "36" "paginaInicial" => "1012" "paginaFinal" => "1022" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25694464" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica de ticagrelor. Available from: <a id="intr0015" class="elsevierStyleInterRef" href="http://www.aemps.gob.es/cima/pestanias.do?metodo=accesoAplicacion">http://www.aemps.gob.es/cima/pestanias.do?metodo=accesoAplicacion</a> [accessed 26.10.15]." ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatina" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "K. Kido" 1 => "M.B. Wheeler" 2 => "A. Seratnahaei" 3 => "A. Bailey" 4 => "J.A. Bain" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Pharm Assoc (2003)" "fecha" => "2015" "volumen" => "55" "paginaInicial" => "320" "paginaFinal" => "323" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000014600000010/v1_201609110046/S2387020616303631/v1_201609110046/en/main.assets" "Apartado" => array:4 [ "identificador" => "43309" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000014600000010/v1_201609110046/S2387020616303631/v1_201609110046/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616303631?idApp=UINPBA00004N" ]
